Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
102.57
-0.12 (-0.12%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
26
27
Next >
3 High Dividend Stocks With Attractive Total Return Potential
March 10, 2023
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns.
Via
InvestorPlace
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via
News Direct
Topics
Economy
Exposures
Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 07, 2023
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics.
Via
Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
March 06, 2023
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry.
Via
InvestorPlace
This High-Yielding Blue Chip Stock Is a Strong Buy
February 13, 2023
This big pharma company pays a market-topping dividend to shareholders.
Via
The Motley Fool
Top CRISPR Stocks
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
February 01, 2023
NVS earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
February 01, 2023
Via
Benzinga
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
March 03, 2023
Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.
Via
Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via
Talk Markets
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
February 24, 2023
Via
Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
February 22, 2023
The two clinical-stage gene-editing companies have good long-term prospects.
Via
The Motley Fool
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
Via
Benzinga
A Preview Of Novartis's Earnings
January 31, 2023
Via
Benzinga
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
February 03, 2023
The major indexes continued to run despite mixed-to-weak earnings.
Via
Investor's Business Daily
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
February 02, 2023
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging.
Via
Benzinga
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
February 01, 2023
Two of the three companies easily beat sales and earnings expectations, but sales fell for the third.
Via
Investor's Business Daily
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors
February 01, 2023
Futures trading point to a negative start by Wall Street stocks on Wednesday as traders exercise restraint ahead of the Fed decision due in the afternoon. Cues From Tuesday’s Trading:
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump
January 30, 2023
Koninklijke Philips NV (NYSE: PHG) would reduce its workforce by an additional 6,000 roles globally by 2025, of which 3,000 will be implemented in 2023 to restore its profitability following a recall...
Via
Benzinga
Earnings Scheduled For February 1, 2023
February 01, 2023
Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.
Via
Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Via
Benzinga
Could This Be Novartis' Next Blockbuster Medicine?
January 27, 2023
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
Via
The Motley Fool
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
January 24, 2023
Via
Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.
Via
InvestorPlace
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
January 19, 2023
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Via
Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
January 19, 2023
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.
Via
Benzinga
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
January 10, 2023
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.
Via
Benzinga
3 Biotech Companies to Watch in 2023
January 06, 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.
Via
InvestorPlace
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.